Biofrontera Inc. to Present at Roth MKM 2023 Healthcare Opportunities Conference and Exhibit at Fall Clinical Dermatology Conference
Biofrontera Inc., a leading biopharmaceutical company specializing in dermatologic products, has announced its participation in two upcoming conferences. The company’s management will deliver a presentation and hold investor meetings at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023, in New York City. Additionally, Biofrontera will exhibit three posters at the 43rd Annual Fall Clinical Dermatology Conference, taking place from October 19-22, 2023, in Las Vegas, Nevada.
The Roth MKM 2023 Healthcare Opportunities Conference provides an excellent platform for Biofrontera to showcase its innovative dermatologic products and engage with potential investors. The company’s management will be available for one-on-one meetings to discuss Biofrontera’s portfolio and future growth prospects.
At the Fall Clinical Dermatology Conference, Biofrontera will present three posters highlighting the findings from research on photodynamic therapy (PDT) using Ameluz® (Ameluz®-PDT). The posters will cover topics such as seasonal and geographical trends in PDT utilization, long-term data from a randomized controlled trial, and the outcomes of combining red-light photodynamic therapy with microneedling for the treatment of facial actinic keratosis.
Biofrontera’s commitment to advancing dermatologic treatments through research and development is evident in its participation in these conferences. By sharing their findings and engaging with industry professionals, the company aims to contribute to the advancement of dermatologic care.
Biofrontera Inc. focuses on commercializing a range of products for the treatment of dermatologic conditions, with a particular emphasis on photodynamic therapy and topical antibiotics. Their licensed products are used to address actinic keratoses, pre-cancerous skin lesions, and impetigo, a bacterial skin infection.
For more information about Biofrontera and its portfolio of products, please visit their website at www.biofrontera-us.com. Stay updated on the latest news and developments by following Biofrontera on LinkedIn and Twitter.
LHA Investor Relations
Tirth T. Patel